Proposals to Reduce Impacts of University Opening for Naresuan University When the COVID-19 Vaccine is not Sole Factor for Opening
Article Sidebar
Main Article Content
Abstract
“Education” is the key for country development and progress. Therefore, protecting students' safety is a primary mission of the university. While Thailand's vaccination policy for the COVID-19 is moving forward and can cover more and more groups of the population, it's the right moment that takes courage to come up with the important policy i.e., “opening educational institutions at all levels” in the midst of COVID-19 pandemic. However, strong policies must be supported by the readiness of those who implement the policy. Good planning will lead to smooth implementation of the policy, even if it is not yet known where it will lead. This article highlights the efforts of Naresuan University to deal with the crisis and to enable effective education under COVID-19 pandemic. It outlines three concrete solutions for problems that may arise after the opening of the university: 1) Immunity passport 2) cleanliness and social distancing by using engineering and architecture design, and 3) Adjusting and directing airflow to control and monitor the quality of the indoor environment using innovation and cooperation from the university community.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Iyer P, Aziz K, Ojcius DM. Impact of COVID-19 on dental education in the United States. J Dent Educ. 2020; 84: 718-22.
Deery C. The COVID-19 pandemic: implications for dental education. Evid Based Dent. 2020; 21: 46-7.
Codding RS, Collier-Meek M, Jimerson S, Klingbeil DA, Mayer MJ, Miller F. School psychology reflec- tions on COVID-19, antiracism, and gender and racial disparities in publishing. Sch Psychol 2020;35 : 227-32.
Caturvedi K, Vishwakarma DK, Singh N. COVID-19 and its impact on education, social life and mental health of students: A survey. Child Youth Serv Rev. 2021; 121: 105866.
Marome W, Shaw R. COVID-19 response in Thailand and its implications on future prepared ness. Int J Environ Res Public Health. 2021; 18: 1089.
Songsivilai S. Application for vaccine support for personnel in the higher education, science, research and innovation sectors [online]. 2021 [cited Sep 17, 2021]. Available from: www.ops.go.th/main/images/ %E0%B8%9E%E0%B8%A8_%E0%B8%81%E0%B8%AD%E0%B8%81_64/%E0%B8%AD%E0%B8%A7_0221.6-%E0%B8%A7_168.pdf
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020; 383: 2320-32.
Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021; 397: 682-94.
AnGes I. Study of COVID-19 DNA vaccine (AG0301-COVID19) [online]. 2020 [cited Aug 24, 2020]. Ava- ilable from: ClinicalTrials.gov/show/NCT04463472.
Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recomb-i nant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396: 479-88.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Oxford COVID vaccine trial group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397: 99-111.
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398: 213-22.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021; 21: 39-51.
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384: 403-16.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020; 383: 2603-15.
Brown RCH, Kelly D, Wilkinson D, Savulescu J. The scientific and ethical feasibility of immunity passports. Lancet Infect Dis. 2021; 21: e58-e63.
Khoshkam Z, Aftabi Y, Stenvinkel P, Paige Lawrence B, Rezaei MH, Ichihara G, et al. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection. J Adv Res 2021; 31: 49-60.
Chien LC, Beÿ CK, Koenig KL. Taiwan's successful COVID-19 mitigation and containment strategy: Achieving quasi population immunity. Disaster Med Public Health Prep [online]. 2020 [cited Sep 17, 2021]. Available from: www.cambridge.org/core/jour nals/disaster-medicine-and-public-health-preparedne ss/article/taiwans-successful-covid19-mitigation-and-containment-strategy-achieving-quasi-population-im munity/0123549586C95DCC93C77E5EF1F613D5
Andiyan A. Architectural design approach to social life patterns after the COVID-19 pandemic. In: Rah mat A, Manurung RT, editors. Community service in the midst of the COVID-19. India: Novateur Publica tion; 2021. p. 8-17.
Reshma VG, Syama S, Sruthi S, Reshma SC, Remya NS, Mohanan PV. Engineered nanoparticles with antimicrobial property. Curr Drug Metab 2017; 18: 1040-54.
SanJuan-Reyes S, Gómez-Oliván LM, Islas-Flores H. COVID-19 in the environment. Chemosphere. 2021; 263: 127973.
Zambrano-Monserrate MA, Ruano MA, Sanchez-Alcalde L. Indirect effects of COVID-19 on the environment. Sci Total Environ. 2020; 728: 138813.
Chen CY, Chen PH, Chen JK, Su TC. Recommen dations for ventilation of indoor spaces to reduce COVID-19 transmission. J Formos Med Assoc [online]. 2021 [cited Sep 17, 2021]. Available from: www.sciencedirect.com/science/article/pii/S092966462100365X. doi.org/10.1016/j.jfma.2021.08.007
Rachapradit N, Poowaruttanawiwit P, Sirilak S, But thum B, Wannalerdsakun S. Prototype of patient room with capability to control parameters affecting indoor air quality: A Pilot study at Naresuan University Hospital. 2022; 14: in press.
Berry G, Parsons A, Morgan M, Rickert J, Cho H. A review of methods to reduce the probability of the airborne spread of COVID-19 in ventilation systems and enclosed spaces. Environ Res. 2021; 203: 111765.
Pan Y, Du C, Fu Z, Fu M. Re-thinking of enginee ring operation solutions to HVAC systems under the emerging COVID-19 pandemic. J Build Eng 2021; 43: 102889.
